• Analyst Coverage
• Corporate Governance
• Email Alerts
• FAQ
• Financial Reports
• Fundamentals
• Image Library
• Information Request
• Investor Events
• SEC Filings
• Presentation Archive
• Press Releases
• Stock Chart
• Stock Quote
• Worth Noting

Current | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

Celera Genomics Launches Advanced Version of Celera Discovery System
Offers Researchers a Powerful New Approach to Access and Mine Celera’s Genomic Information Including Human and Mouse Genomes

Rockville, MD - January 18, 2001

Celera Genomics (NYSE: CRA), an Applera Corporation business, announced today it has launched a new version of the Celera Discovery System (CDS). This system provides Celera subscribers convenient desktop access to Celera’s proprietary genome data, advanced research tools, and supercomputing facility via the Internet.

The CDS features an integrated view of the assembled human genome sequence and its catalog of human genes and proteins generated through proprietary computational methods with further refinement and on-going analysis by Celera’s scientists. The CDS Biomolecule Report is the main viewing application for CDS that gives researchers the capability to integrate information about each gene and protein structure, function and role in normal physiological and disease processes. The Celera mouse genome sequence is another important CDS feature used for the accurate annotation of human genes in Celera’s high quality computational and hand curated gene predictions.

“The new version of the Celera Discovery System offers a flexible discovery platform that should enable life sciences researchers to identify genes important to their specific research programs, and to understand their function and role in human disease. This is accomplished by combining comprehensive data with the review and annotation of human genes and proteins by Celera scientists and bioinformatics experts,” said J. Craig Venter, Ph.D., Celera’s president and chief scientific officer. “CDS provides our subscribers with a novel approach to exploring genome-scale data now, and it lays the foundation to expand and integrate gene expression and proteomics data, protein structure, genetic variation, scientific literature and other data and information sources as the product evolves to meet our customers’ needs.”

“The Celera Discovery System provides a major improvement in the user interface to Celera's integrated DNA sequence databases. The new computational tools bundled in this release will enable investigators to more efficiently mine the Celera data, thereby enhancing their research programs,” said Mark A. Magnuson, M.D., Assistant Vice-Chancellor for Research at Vanderbilt University, a subscriber of the Celera Discovery System.

About CDS
The Celera Discovery System is an integrated, web-based discovery system that allows subscribers to use Celera-generated databases, additional non-proprietary genome and biological datasets, as well as computational tools and super-computing power to advance the discovery programs of researchers worldwide.

Specific genome databases and tools include:

• The assembled human genome sequence
• Catalogs of known human genes, transcripts, proteins
• A database of mapped human single nucleotide polymorphisms
• Mouse genome sequence (assembly and subsequent validation under development)
• Mouse gene index
• The assembled D. melanogaster genome sequence
• Catalogs of D. melanogaster genes, transcripts, and proteins
• 34 additional non-proprietary databases (e.g., GENBANK, SWISSPROT, and other sequence, motif, structure, and mapping databases), updated regularly
• Classification of proteins into families using proprietary algorithms
• Classification of proteins into the Gene Ontology program
• Sequence similarity, motif, and pattern searches
• Comparative analyses across complete genomes
• Access to Celera’s supercomputing facility

For a virtual tour of the Celera Discovery System, log onto www.discovery.celera.com or call 1-888-545-8808 for more information.

About Celera
Applera Corporation, formerly PE Corporation, comprises two operating groups. The Celera Genomics Group, headquartered in Rockville, MD, intends to be the definitive source of genomic and related medical information. Celera has developed three business units: the On-line Information Business, Discovery Sciences, and Discovery Services, all of which build upon Celera’s generation, integration, and analysis of biological information. Celera intends to enable therapeutic discoveries both through its own application of its scientific capabilities and in partnership with pharmaceutical and biotechnology companies. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Customers use these tools to analyze nucleic acids (DNA and RNA) and proteins in order to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.4 billion during fiscal 2000. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning 800.762.6923.

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "anticipate," "should," "planned," "estimated," and "potential," among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of Celera Genomics' businesses include but are not limited to (1) operating losses to date; (2) a unique and expanding business plan; (3) dependence on the final assembly and annotation of the human genome; (4) uncertainty of revenue growth; (5) unproven use of genomics information to develop products; (6) intense competition in the evolving genomics industry; (7) dependence on customers in and subject to the risks of the pharmaceutical and biotechnology industries; (8) heavy reliance on strategic relationship with the Applied Biosystems Group; (9) lengthy sales cycle; (10) dependence on the unique expertise of its scientific and management staff; (11) uncertainty of patent, copyright, and intellectual property protection; (12) dependence on computer hardware, software, and internet applications; (13) access to biological materials; (14) legal, ethical, and social issues affecting demand for products; (15) disruptions caused by rapid growth of the business; (16) government regulation of its products and services; (17) risks of future acquisitions; (18) uncertainty of outcome of stockholder litigation; and (19) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission.

Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.